BioOutsource Expands ADC Characterisation Capabilities

Contract testing organisation BioOutsource has amplified its position as a global leader in antibody drug conjugates (ADC) characterisation and announced a partnership with Glythera Ltd, an emerging biotechnology company based in Newcastle-upon-Tyne, UK, that specialises in the development of next generation biotherapeutics through the application of its proprietary linker and stable glycan technologies.

BioOutsource CSO Daniel Galbraith commented: “Building on our position as a leader in biological characterisation of monoclonal antibodies, ADC’s represent an exciting development that will enhance the performance of a wide range of therapeutic products. We are delighted to partner with Glythera to characterise their ADC product in development, as we believe it holds considerable promise.”

Glythera COO Dr. David Simpson highlighted the value of the collaboration: “We are delighted to have the opportunity to work with BioOutsource on their ADC characterisation as it is an area where our linker technologies offer significant benefits. This partnership demonstrates recognition of these powerful capabilities and we look forward to working with BioOutsource on this exciting project.”

BioOutsource Ltd, +44 141 946 4222, gfulton@biooutsource.com, www.biooutsource.com.